Pharmacopsychiatry 2004; 37: 141-147
DOI: 10.1055/s-2004-832668
Schizophrenia
© Georg Thieme Verlag KG Stuttgart · New York

Mechanisms of Relapse Prevention in Schizophrenia

N. Müller1
  • 1Department of Psychiatry and Psychotherapy, Ludwig-Maximilians University, Munich, Germany
Further Information

Publication History

Publication Date:
16 November 2004 (online)

Introduction: A relapse can be expected in 70 % of patients after the first schizophrenic episode; in parallel 70 % of patients show an incomplete remission of the disorder after the first episode. This includes a cognitive decline and persistence of schizophrenic negative symptoms, often associated with social disabilities, social decline and a worsened quality of life. The risk for a relapse after a schizophrenic episode remains increased throughout the patient’s lifetime. Moreover, the risk for chronic disorder increases with every relapse of the patient. Therefore relapse prevention is a primary focus in the treatment of schizophrenia. Methods: Studies point out that atypical antipsychotics have advantages in relapse prevention of schizophrenia compared to the ‘classical’ antipsychotics, although comparative studies are still lacking. Results: The main risk factor for a relapse is the withdrawal of antipsychotic medication. Nonbiological factors such as high-expressed emotions, adverse life events and stress contribute to an increased risk of schizophrenic relapse. Studies of relapse after withdrawal of antipsychotic medication revealed that noradrenergic, serotonergic, and dopaminergic neurotransmission are involved, low serotonergic and high dopaminergic neurotransmission are associated with a relapse, and possibly high noradrenergic neurotransmission plays a role in short-term relapses. Inflammation and the activation of certain cytokines, which have rarely been studied to date, seem to have an even higher impact on schizophrenic relapse. Methodological aspects of these studies are discussed. Conclusion: Biological mechanisms of relapse may not become fully elucidated before the mechanisms of the schizophrenic pathophysiology are clarified.

References

  • 1 American Psychiatric A ssociation. Practise guideline for the treatment of patients with schizophrenia.  Am J Psychiatry. 1997;  154 (Suppl 4) S1-S63
  • 2 Angrist B, Peselow E, Rotrosen J, Gershon S. Relationships between responses to dopamine agonists, psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects.  Rec Adv Neuropsychopharmacol Adv Biosci. 1981;  31 49-54
  • 3 Bailer J, Rist F, Brauer W, Rey E R. Patient rejection scale: correlations with symptoms, social disability and number of re-hospitalizations.  Eur Arch Psychiatry Clin Neurosci. 1994;  244 45-48
  • 4 Bebbington P, Kuipers L. The predictive utility of expressed emotions in schizophrenia: an aggregate analysis.  Psychol Med. 1994;  24 707-718
  • 5 Bosveld-van Haandel L JM, Slooff C J, van den Bosch R J. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.  Acta Psychiatr Scand. 2001;  103 335-346
  • 6 Csernansky J G, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.  N Engl J Med. 2002;  346 16-22
  • 7 Davidson M, Keefe R SE, Mohs R, Siever L J, Losonczy M F, Horvarth T B, Davis K L. L-dopa challenge and relapse in schizophrenia.  Am J Psychiatry. 1987;  144 934-938
  • 8 Davis J M, Mentalon L, Watanabe M D. Depot antipsychotic drugs: place in therapy.  Drugs. 1994;  47 741-773
  • 9 Docherty J P, van Kammen D P, Siris S G, Marder S T. Stages of onset of schizophrenic psychoses.  Am J Psychiatry. 1978;  135 420-426
  • 10 Doering S, Müller E, Köpcke W, Pietzcker A, Gaebel W, Linden M, Müller P, Müller-Spahn F, Tegeler J, Schüssler G. Predictors of relapse and re-hospitalization in schizophrenia and schizoaffective disorder.  Schizophrenia Bull. 1998;  24 87-98
  • 11 Dutch Schizophrenia F oundation. Consensus document. The Netherlands; Schizophrenia Foundation 1996
  • 12 Gaebel W, Falkai P (eds.) Praxisleitlinien in Psychiatrie und P sychotherapie. Behandlungsleitlinie Schizophrenie. Darmstadt; Steinkopff-Verlag 1998
  • 13 Gattaz W F, Abrahao A L, Foccacia R. Childhood meningitis, brain maturation and the risk of psychosis. Eur Arch Psychiatry Clin Neurosci 2003 (in press)
  • 14 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.  Br Med J. 2000;  321 1371-1376
  • 15 Glazer W M, Kane J M. Depot neuroleptic therapy: an underutilized treatment option?.  J Clin Psychiatry. 1992;  53 426-433
  • 16 Hogarty G E. Prevention of relapse in chronic schizophrenic patients.  J Clin Psychiatry. 1993;  54 (Suppl 3) 18-23
  • 17 Hogarty G E, Schooler N R, Ulrich R F, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of a two-year controlled study of fluphenazine-decanoate and fluphenazine hydrochloride.  Arch Gen Psychiatry. 1979;  36 1283-1294
  • 18 Kelley M E, Yao J K, van Kammen D P. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in Schizophrenia.  Neuropsychopharmacol. 1999;  20 603-611
  • 19 Kissling W ( ed). Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin, NY; Springer Verlag 1991
  • 20 Kissling W, Kane J M, Barnes T R, Dencker K, Fleischhacker W W, Goldstein J M, Johnsom D AW, Marder S R, Müller-Spahn F, Tegeler J, Wilstedt B, Woggon B. Guidelines for neuroleptic relapse prevention in schizophrenia: towards consensus view. in: Kissling W (ed) Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin, NY; Springer Verlag 1991: pp 155-163
  • 21 Leucht S, Barnes T RE, Kissling W, Engel R R, Correll C, Kane J M. Relapse prevention in schizophenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.  Am J Psychiatry. 2003;  160 1209-1222
  • 22 Lieberman J A, Kane J M, Gadaletta D. Methylphenidate challenge tests and course of schizophrenia.  Psychopharmacol Bull. 1985;  21 123-129
  • 23 Lieberman JA Koreen A R, Chakos M, Sheitman B, Woerner M, Alvir J MJ, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.  J Clin Psychiatry. 1996;  57 (Suppl 9) 5-9
  • 24 McEvoy J P, Scheifler P L, Frances A ( eds). The expert consensus guideline series. Treatment of schizophrenia 1999.  J Clin Psychiatry. 1999;  60 (Suppl 11)
  • 25 Müller N. Neuroimmunology of schizophrenia. In: D’Haenen H, den Boer JA, Willner P (eds) Biol Psychiatry. J Wiley & Sons 2002: pp 613-623
  • 26 Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine-network in the CNS: implications for psychiatric disorders.  Prog Neuropsychopharmacol Biol Psychiatry. 1998;  22 1-33
  • 27 Müller N, Riedel M, Scheppach C, Brandstätter B, Sokkullu S, Krampe K, Ulmschneider M, Möller H -J, Schwarz M. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.  Am J Psychiatry. 2002;  159 1029-1034
  • 28 Müller N, Ulmschneider M, Scheppach C, Schwarz M J, Ackenheil M, Möller H -J, Gruber R, Riedel M. COX-2 Inhibition as Treatment Approach in Schizophrenia: Immunological Considerations and Clinical Effects of Celecoxib add-on Therapy.  Eur Arch Psychiatry Clin Neurosci. 2004;  254 14-22
  • 29 Müller-Spahn F. Neuroendokrinologie und Schizophrenieforschung. Berlin, NY; Springer Verlag 1989
  • 30 McAllister C G, van Kammen D P, Rehn T J, Miller A L, Gurklis J A, Kelley M D, Yao J K, Peters J F. Increases in CSF levels of Interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.  Am J Psychiatry. 1995;  152 1291-1297
  • 31 Nuechterlein K H, Dawson M E, Ventura J, Gitlin M, Subotnik K L, Snyder K S, Mintz J, Bartzokis G. The vulnerability/stress model of schizophrenic relapse: alomgitudinal study.  Acta Psychiat Scand. 1994;  (Suppl 382) 58-64
  • 32 Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.  Am J Psychiatry. 2001;  158 266-269
  • 33 Rantakallio P, Jones P, Moring J, Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up.  Int J Epidemiol. 1997;  26 837-843
  • 34 Robinson D, Woerner M G, Alvir J MJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman J A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.  Arch Gen Psychiatry. 1999;  56 241-247
  • 35 Sartorius N, Gulbinat W, Harrison G, Laska G, Siegel C. Long-term follow-up of schizophrenia in 16 countries: a description of the International Study of Schizophrenia conducted by the World Health Organisation.  Soc Psychiatry Psychiatr Epidemiol. 1996;  31 249-258
  • 36 Schaub A. Relapse and coping behavior in schizophrenia.  Schizophrenia Res. 1994;  11 188
  • 37 Schaub A. Coping-Forschung und bewältigungsorientierte Therapien bei schizophrenen Störungen. In: Bäuml J, Pitschl-Walz G (Hrsg) Psychoedukation bei schizophrenen Erkrankungen. Schattauer. Stuttgart, NY; 2003: pp 173-203
  • 38 Szymanski H V, Simon J C, Gutterman N. Recovery from schizophrenic psychosis.  Am J Psychiatry. 1983;  140 335-338
  • 39 van Kammen D P, Kelley M D, Gurklis J A, Gilbertson M K, Yao J K, Peters J F. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.  Arch Gen Psychiatry. 1995;  52 673-678
  • 40 van Kammen D P, Kelley M D, Gurklis J A, Gilbertson M K, Yao J K, Condray R, Peters J F. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.  Neuropsychopharmacol. 1996;  14 603-611
  • 41 van Kammen D P, Peters J F, van Kammen W B, Nugent A, Goetz K L, Yao J K, Linnoila M. CSF Norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry 1989: 176-188
  • 42 Wiersma D, Nienhuis F J, Sloof C J, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort.  Schizophr Bull. 1998;  24 75-85
  • 43 Zhang-Wong J, Beiser M, Bean G, Iacono W G. Five-year course of schizophreniform disorder.  Psychiatry Res. 1995;  59 109-117
  • 44 Zubin J, Steinhauer S R, Day R, van Kammen D P. Schizophrenia at the crossroads: A blueprint of the 80’s.  Compr Psychiatry. 1985;  26 217-240

Prof. Dr. med. Dipl.-Psych. Norbert Müller

Department of Psychiatry and Psychotherapy

Ludwig-Maximilians University

Nußbaumstr. 7

80336 Munich

Germany

Phone: +49 89 5160 3397

Fax: +49 89 5160 4548

Email: norbert.mueller@med.uni-muenchen.de